Nanoparticles in Cutting-edge Healthcare: Current Use and Emerging Issues

Authors

  • Kirandeep Kaur

Abstract

Nanoparticles are sub-micron-sized particles (less than 100 nm on average). Using these materials as contrast agents in imaging and as carriers for medication and gene transfer into malignancies has given them a prominent place in contemporary medicine. Nanoparticles allow for previously inconceivable levels of analysis and therapy. However, nanoparticles provide new societal and environmental challenges, especially regarding toxicity. In this overview, we discuss how nanoparticles have benefited contemporary medicine and how they have threatened our planet and our way of life. For the past three decades, nanotechnology has been a popular subject for academic discussion. Because of their unique optical, electrical, magnetic, chemical, and biological capabilities, nanoscale materials, which are about 10,000 times smaller than the width of a hair strand, are attracting much attention. It has been shown that nanoparticles have potential in preclinical settings, and techniques have been developed for synthesizing and characterizing vast collections of nanomaterials. Nanomedicine research has entered a new era, and now we can devote our efforts to helping people. This article details the development of nanomedicine, its present condition, and the difficulties associated with using its findings in clinical practice. We wrap up by explaining why it is so important for doctors and engineers to work together to create a two-way data flow between the laboratory and the hospital. As a result of this collaboration, novel medication delivery systems, sensors, imaging agents, and treatment systems will be developed and evaluated with more efficiency and accuracy than ever before.

References

Roof KS, Coen J, Lynch TJ, Wright C, Fidias P, Willett CG, Choi NC. Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat

Oncol Biol Phys. 2006; 65: 1120–1128.

Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett. 2004; 4: 11–18.

Rudolph C, Schillinger U, Ortiz A. Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm Res. 2004; 21:

–1669.

Goodman CM, Mccusker CD, Yilmaz T. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjugate Chem. 2004; 15: 897–900.

Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Goletti D, Baroncelli S, et al.. Control of SHIV- 89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med. 2009; 5 (6):643–650.

KreuterJ, Ramge P, Petrov V. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to

the nanoparticles. Pharm Res. 2003; 20: 409–416.

Siegemund T, Paulke BR Schmiedel H. Thioflavins released from nanoparticles target fibrillar amyloid beta in the hippocampus of APP/PS1 transgenic mice. Int J Dev Neurosci. 2006; 24: 195–

Muldoon L, Sandor M, Pinkston KE. Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. Neurosurgery.

; 57: 785–796.

Tomonaga M, OM, Narasaki F, Fukuda M, Nakano R, Takatani H, et al. The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers. Jpn J Cancer Res. 2009; 87: 1263–1270.

Zhang W, Yang H, Kong X, Mohapatra S, San Juan-Vergara H, Hellermann G, et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1

gene. Nat Med. 2005; 11 (1): 56–62.

Caputo A, Gavioli R, Ensoli B. Recent advances in the development of HIV-1 Tat-based vaccines. Curr HIV Res. 2004; 2: 357–376.

Owens DE, Peppas NA. Opsonization, biodistribution, and pharma-cokinetics of polymeric nanoparticles. Int J Pharm. 2006; 307: 93–102.

De Jaeghere F, Allémann E, Kubel F, Galli B, Cozens R, Doelker E, Gurny R. Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state. J Control Release. 2000; 68 (2): 291–298.

Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 2006; 1 (3): 325–327.

Nam YS, Park JY, Han SH. Intracellular drug delivery using poly(D,L-lactide-co-glycolide) nanoparticles derivatized with a peptide from a transcriptional activator protein of HIV-1. Biotechnol Lett. 2002; 24: 2093–2098.

Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003; 2 (3): 214–221.

Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002; 54: 631–651.

Witt KA, Huber JD, Egleton RD, Davis TP. Pluronic P85 block copolymer enhances opioid peptide analgesia. J Pharmacol Exp Ther. 2002; 303 (2): 760–767.

Torchilin VP, Weissig V, editors. Liposomes (Practical Approach). Oxford, UK: Oxford University Press; 2003.

Mornet M, Vasseur S, Grasset F. Magnetic nanoparticle design for medical diagnosis and therapy. J Mater Chem. 2004; 14: 2161–2175.

Plard JP, Bazile D. Comparison of the safety profiles of PLA(50) and Me.PEG-PLA(50) nanoparticles after single dose intravenous administration to rat. Colloid Surf B Biointerfaces.

; 16: 173–183.

Neuberger T, Schopf B, Hofmann H. Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. J Magn Magn Mater. 2005; 293:

–496.

Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown JV 3rd. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol, 2006; 100 (2): 437–438.

Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan WCW. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016; 1: Article 16014.

Duan L, Ouyang K, Xu X, Xu L, Wen C, Zhou X, Qin Z, Xu Z, Sun W, Liang Y. Nanoparticle delivery of CRISPR/Cas9 for genome editing. Front Genet. 2021; 12: 673286.

Merodio, M, Irache JM, Valamanesh F. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials. 2002; 23: 1587–1594.

Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2009; 53 (2): 283–318.

Akerman ME, Chan WCW, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A. 2002; 99 (20): 12617–12621.

Abratt RP, Lee JS, Ha JY, Tsai C-M, Boyer M, Mok T, et al. Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer. J Thorac Oncol. 2006; 1 (2): 135–140.

Downloads

Published

2023-10-01

Issue

Vol. 11 No. 3 (2023)

Section

Review Articles

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.